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Asymptomatic shedding of herpes simplex virus (HSV) 
a! delivery occurred in 2.4% of women with a past 
hIstory of recurrent genital infections; using current 
methods, this could not be predicted in advance. In ad­
dition, only 22% of the mothers of infected infants had 
an elicitable history of recurrent genital infections. Pas­
sively derived neutralizing antibody titers of 1: 106 to 
HSV-l and 1:67 to HSV-2 were found in 22 exposed 
infants who remained asymptomatic as compared with 
1:8 and 1:8, respectively, in ill infants, suggesting that 
transfer of antibody from the mother may be an impor­
t�nt .
host d
.
efense .
. 
Among treated infants, a more rapid 
rise m antibody titer was seen in infants receiving ad­
enine arabino
,
side than in those receiving acyclovir; two 
of the latter mfants developed a severe infection in a 
sec
.
ond organ following cessation of the drug. Exposure 
of mfants to HSV appears inevitable at this time. The 
extreme variability in outcome is probably related to 
host factors that are poorly understood at present. 
The episodic nature of overt cutaneous attacks due to infec­
tion with herpes simplex virus is well accepted, but the episodic 
nature of
. 
asymptomatic shedding is less well appreciated [1,2]. 
The predictability of symptomatic shedding of HSV is of par­
t.lcular concern in pregnant women who have recurrent genit.al 
mfectlOns due to herpes simplex virus or who have initial 
attacks of infection during pregnancy. It is estimated that at 
least 1 per 1000 pregnant women shed HSV asymptomatically; 
however, the attack rate among neonates is estimated at only 
1 per 7500 births [ 3]. The latt.er figure may be an underesti­
mation; it is known that up to 50% of neonatal cases lack 
cuta.neous involvement and may not be diagnosed [ 4]. This is 
particularly true for the disseminated form of the disease in 
whi�h the sudden onset. of hepatosplenomegaly, thromboc;to­
pema, bleeding diathesis, and hepatic dysfunction may be as­
sumed t.o be due to bact.erial sepsis. 
In adults with recurrent HSV infections, treatment wit.h the 
available antiviral agents only shortens the period of viral 
s�eddin
.
g slightly and does not decrease the period of pain and 
dlscomtor� [5]. Research has centered on eradicating latency. 
Investlg�tlOns of the factors responsible for restricting HSV to 
a focal site of latency have received little emphasis. In severe 
infections, such as are seen in the neonate, antiviral therapy 
has altered the natural course of the disease, and infants now 
survive the infection who would have previously expired. It is 
apparent that entering and maintaining a state of latency is, in 
tact, a successful response on the part of the host. 
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ASYMPTOMATIC SHEDDING IN PREGNANT 
WOMEN 
Rates of shedding of HSV in consecutively studied pregnant 
w.omen range from less than 1 per 1000 to 4 per 100 [6-8]. The higher rate was obtained in a study performed in a population 
?f low socioeconomic status that was primarily Spanish-speak­
mg; no attempt was made to determine whether these women 
had had genital HSV infections in the past. Two studies of 
asymptomatic shedding of HSV have been performed in preg­
nant women known to have recurrent genital infections caused 
by HSV. Vontver et al isolated HSV from 0.66 % of cervical 
cultures and from 0.75% of vulvar cultures obtained during 
asymptomatic periods [9]. Harger et al isolated HSV from 2.:3% 
of cultures taken during asymptomatic periods [10]. Women 
who had their initial attack during the current pregnancy or 
women whose sole evidence of infection was asymptomatic were 
included in these studies [9;10]. 
Cul�ure result� cannot be reliably reported until 4 days 
followmg receipt m the laboratory [11]. The assumption behind 
the recommendation to perform cultures for asymptomatic 
shedding during pregnancy is that they have some predictive 
value. This would be so if the period of asymptomatic shedding 
was prolonged; this does not seem to be the case. Sher et al and 
Vontver et al recultured 12 pregnant patients with asympto­
matic shedding within 7 days of the positive culture [8,9]. All 
fol.low-up cultures were negative except for one; this patient's episode of asymptomatic shedding terminated between the 
seventh and fourteenth day [8,9]. Likewise, we have recultured 
7 pregnant women with asymptomatic antepartum shedding 
wlthm a week, and all the follow-up cultures were negative 
[12]. 
Cultures for asymptomatic shedding would be of value if 
certain women tended to shed more frequently than others 
thus predicting a population more likely to be shedding at term : 
The data we have accumulated to date through collaboration 
with the obstetricians participating in the Stanford Perinatal 
Herpes SiI?plex Program suggest that this is not the case [12]. 
As shown m Table I, asymptomatic shedding of HSV occurred 
antepartum in women who had attacks during the current 
pregnancy as well as in women who did not. Positive cultures 
were obtained from asymptomatic women more frequently from 
the usual site of the lesion than from the cervix. When these 
women were recultured at delivery, HSV was not isolated. 
�owever, the overall prevalence of shedding at delivery was 
Similar to the antepartum period (2. 4%) [13]. The women 
shedding at delivery did not have HSV isolated during asymp­
tomatic periods during pregnancy. 
SOURCE OF INFECTION IN THE INFANT 
The premise that all infections in the infant can be avoided 
by carefully screening the obstetric population is incorrect. As 
shown in Table II, a history consistent with recurrent O'enital 
infections could only be elicited from 8 (22'1(,) of the rn"'others 
of infected infants [4,14]. Mothers with primary oral or genital 
mfectlOns account for 33'1;;. of the cases. A non maternal source 
was documented in 8.3';;;' of the cases in this series [4,15]. 
Transmission of HSV from father to infant has also been 
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TABLE l. Incidence of asymptomatic shedding of H8 V in pregnant 
1I'()men with rf'current genital infections 
Asymptomatic shedding antepartum 
Antepartum attacks during preg­
nancy No. positive/no. tested (%) 
Overt attacks; culture proven 
No overt attacks; last attack 
prior to pregnancy 
10/338 (2.95%) 
1/62 (1.6%) 
TABLE II. Summary of sources of neonatal HSV infection in 36 cases 
Source of infection in 36 cases of acquired HSV infection in neonates 
Contact 
Mother 
Father 
Nonmaternal 
Unknown 
Circumstances No. of cases ------
Elicitable history of recurrent 
genital HSV in mother 
Primary HSV in mother-oral 
3, genital 9 
Shedding HSV despite lack of 
clinical evidence of recurrent 
or primary genital infection 
Antepartum history of recurrent 
HSV infections on buttock; 
etiology proved postpartum 
Postpartum recurrences without 
antepartum history 
Elicitable history of genital HSV 
in father only 
Father, grandmother, unknown 
8 
12 
3 
-- �--- - ----- .---- -----
TABLE III. Relatiunship of quantity of neutralizing antibody to 
outcome in exposed infants 
Type of case No. 
Mean neutralization 
titer 
Infected infant 
Asymptomatic ex­
posed infant 
All cases 
Overt lesion or 
asymptomatic 
shedding during 
41 
22 
HSV-l HSV-2 ------
1:8 1:8 
1:106 1:67 
vaginal delivery ---�- �----------
described by Douglas et al 1161. Only two of the mothers we 
studied were known to be promiscuous, 
The source of an infant's infection may not necessarily be 
obvious. It is known that persons with oral lesions can carry 
HSV on their hands for hours [17J. In addition, herpetic 
whitlow is an occupational hazard among medical personnel 
[18-19J. HSV may sometimes be on the hands of medical 
personnel at the time of procedures such as intubation and may 
pose a potential risk to neonates. 
RISK OF INFECTION IN THE EXPOSED INFANT 
Severe infections appear to be restricted to infants less than 
4 weeks of age. In animal models there is an age-related 
susceptibility to HSV infections; resistance to a standard in­
oculum increases significantly during the first few weeks of life 
[20-22J. It seems likely that there is a similar age-related 
susceptibility to HSV infections in the human neonate, since 
infants over 4 weeks of age rarely develop severe infections. 
From 80-50% of neonates infected with HSV are premature, 
whereas only 7-15% of neonates in the general population are 
premature 14,14J. The reasons for this are not known. 
For vaginally delivered infants of mothers with culture­
positive genital lesions, the risk of infection correlates with 
whether the mother's infection is primary or recurrent. Nah­
mias et al found a rate of infection of 50% if the mother's lesion 
was primary, but only 4% if the mother's lesion was recurrent 
[23J. Several possible reasons exist for these differences in risk. 
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First, approximately 90% of women with primary HSV infec­
tions shed HSV from the cervix, whereas only 4-5% of women 
with recurrent genital infections shed virus from the cervix 
when lesions are active [9,12,24J. More virus is present at more 
sites in women with primary infections. In addition, in primary 
infections, the mother has often not developed an immune 
response at time of delivery, and therefore, there is no trans­
placental passage of neutralizing antibody to HSV [4J. 
As previously reported, there is a difference in the serum 
neutralization titers in infants exposed to HSV who remain 
well as compared with symptomatic infants [4,25 J. An expanded 
summary of these data are shown in Table IlL The mean titer 
of neutralizing antibody in the serum of infected infants was 
1:8 to HSV -1 and to HSV -2. In comparison, the 22 infants who 
remained asymptomatic following exposure to HSV at the time 
of a vaginal delivery had a mean neutralizing antibody titer in 
serum of 1:106 to HSV-l and 1:67 to HSV-2. All these infants 
were born to mothers with recurrent genital infections. In the 
healthy, term infant, the quantity of neutralizing antibody in 
amniotic fluid correlates with the quantity of antibody present 
in the mother's serum [26J. It is likely that antibody augments 
host resistance if present in sufficient quantity. The mechanism 
of this host defense could include mobilization of cellular re­
sponses through such mechanisms as antibody-dependent cel­
lular toxicity and neutralization [27 J. 
EFFECT OF ANTIVIRAL THERAPY ON LATENCY 
Adenine arabinoside has been shown to improve the outcome 
in infected infants, but both the mortality and the morbidity 
remain high [28J. A current trial comparing adenine arabino-
FIG 1. Case:3 at 71/2 months of age. 
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side with acyclovir is nearing completion. In addition to admin­
istration of an antiviral, development of an immune response 
may be necessary for resolution of the infection, for mainte­
nance of latency, and for restriction of recurrences to cutaneous 
foci. Both humoral and cellular immunity develop in conjunc­
tion with resolution of primary genital infections in adults 
[29]. 
Virtually all infants who have cutaneous lesions during their 
initial course will have cutaneous recurrences. The following 
cases demonstrate some of the other problems with latency and 
recurrences encountered in treated infants. 
Case 1 
This premature infant developed a cutaneous lesion on the chest at 
8 days of age. Following isolation of HSV, a 10-day course of acyclovir 
was given. The cerebrospinal fluid obtained at the onset of therapy 
showed 7 WBCs, a glucose of 73 mg%, and a protein of 80 mg%. The 
lesion healed and the infant was discharged. Twenty-seven days after 
termination of therapy, a cutaneous lesion reappeared at the original 
site and healed over a period of approximately 5 days. Thirty-seven 
days after the termination of therapy, lethargy developed. At this time, 
the cerebrospinal fluid contained 158 WBCs, a glucose of 38 mg%, and 
a protein of 118 mg%. Seizures were demonstrated on electroencepha­
logram. Despite retreatment, the infant sustained severe brain damage. 
Neutralizing antibody to HSV -1 and HSV -2 could not be detected in 
the infant's serum at the onset of the encephalitis despite the docu­
mentation of earlier infection. 
Case 2 
This term infant developed a vesicular lesion on the occiput on the 
second day of life. The cerebrospinal fluid at this time showed 1 WBC, 
a glucose of 51 mg%, and a protein of 105 mg%. The infant received a 
10-day course of acyclovir. On the sixth day of life, a new lesion 
developed despite t.he acyclovir therapy. The infant subsequently did 
well and was discharged. Sixteen days following termination of therapy, 
the infant developed fussiness and fever. The cerebrospinal fluid 
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showed 130 WBCs, a glucose of 67 mg%, and a protein of 43 mg%. 
Subsequently, seizures developed and the cerebrospinal fluid protein 
rose to 620 mg%. The infant was retreated with adenine arabinoside 
but sustained severe brain damage. At the time the encephalitis devel­
oped, neutralizing antibody to HSV -1 and HSV -2 could not be detected 
in the infant's serum. 
Case 3 
This term infant developed an HSV infection on her upper lip at the 
age of 11 days. At the age of 17 days, treatment was begun with adenine 
arabinoside. A new lesion appeared on the tenth day of therapy, and 
the drug was continued for 15 days. At 2� months of age, the infant 
developed a lesion on her upper lip. This lesion healed. At 4 months of 
age, she developed a lesion on her lower lip that progressed over a 1-
month period to a mucosal ulcer 2 x 1 cm in size and � cm deep. During 
this period, a lesion also developed on her upper lip. HSV was isolated 
from both lesions. When she next returned to medical care at 7 months 
of age, she had a wedge-shaped defect in the lower lip with a cutaneous 
fistula from the skin to the mucosa. HSV was not isolated. After a 
period of apparent improvement, the tissue above the fistula ruptured, 
increasing the width and depth of the defect, and a new lesion developed 
on the upper lip (Fig 1). HSV was eventually isolated from both sites. 
The neutralizing antibody titer to HSV-1 was 1:40 and to HSV-2 was 
1:31. HSV lesions had never been noted at sites other than the lip. The 
infant was treated with a lO-day course of acyclovir, and both lesions 
healed. In addition, there was an enormous improvement in her sense 
of well-being, weight gain, and developmental progress. An immuno­
logical workup revealed no definite immune defect. The infant was free 
of other serious infections. At follow-up at 18 months of age, she 
continued to thrive and had occasional small cutaneous recurrences. 
While it is known that the responses in humoral and cellular 
immunity following primary HSV infections are slower in in­
fants than in adults, the possibility that the administration of 
antiviral agents may alter the natural response needs to be 
evaluated [25,29]. Lack of development of neutralizing antibody 
was associated with the development of encephalitis in cases 1 
Adenine Arabinoside 
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FIG 2. Responses in neutralizing antibody in infants treated with acyclovir as compared with those treated with adenine arabinoside. 
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and 2 following termination of acyclovir. As shown in Fig 2, 
the antibody titers of the infants treated with acyclovir per­
sisted at low levels as compared with those treated with adenine 
arabinoside. None of the 11 infants treated with acyclovir had 
developed a titer of 1:20 or higher by the tenth day following 
onset of therapy, while 4 of the 5 infants treated with adenine 
arabinoside had titers above 1:20 by the tenth day. 
In addition to antibody, other factors must be necessary for 
maintenance of latency and for containment at the site of 
recurrences. In case 3, the presence of neutralizing antibody 
correlated with ability to localize the site of infection, but the 
infant had had persistent active infection for 6 months. 
CONCLUSION 
Asymptomatic shedding of HSV at delivery is episodic and 
cannot now be predicted. Not all infants exposed to HSV at 
birth become infected. At present there is no known means of 
preventing infection in infants of mothers who deny a history 
of recurrent genital infections. Cases of neonatal HSV infection 
will continue to occur. The possibility that the immune re­
sponse may be altered by antiviral therapy needs to be inves­
tigated further. Correlation of the lack of ability of some 
neonates to constrain the sites of latency and recurrences to 
small foci with in vitro measurements of the immune responses 
in these cases may lead to a better understanding of latency 
and of the optimal use of antiviral therapy. 
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